Previous 10 | Next 10 |
Of the 23 high-risk allogeneic hematopoietic cell transplant patients in this analysis, no end-organ viral disease was observed Of the 13 patients who completed through the Week 14 primary endpoint, 11 remained free of clinically significant infection Strength of these...
AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced today that the company will participate in the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference. A pre-recorded fireside chat will be available from Monday, November 22 to Thursday, D...
AlloVir (NASDAQ:ALVR): Q3 GAAP EPS of -$0.72. Cash, cash equivalents, and marketable securities of $275.8M Press Release For further details see: AlloVir reports Q3 results
Company is prioritizing prevention and treatment programs with the potential to transform transplant patient care and outcomes Positive interim data from posoleucel multi-virus prevention Phase 2 study will be presented at ASH Posoleucel Phase 3 study for the treatment...
Gainers: Camber Energy (NYSE:CEI) +27%. HCW Biologics (NASDAQ:HCWB) +21%. Fuel Tech (NASDAQ:FTEK) +23%. RedHill (NASDAQ:RDHL) +19%. Harmony (NASDAQ:HRMY) +15%. Ginkgo Bioworks (NYSE:DNA) +15%. Arqit Quantum (NASDAQ:ARQQ) +14%. AlloVir (NASDAQ:ALVR) +13%. ViewRay (NASDAQ:VRAY) +13%. Full Truck...
Gainers: AlloVir (NASDAQ:ALVR) +14%, InflaRx (NASDAQ:IFRX) +14%, Harmony Biosciences (NASDAQ:HRMY) +13%, Omeros (NASDAQ:OMER) +11%, Prelude Therapeutics (NASDAQ:PRLD) +11%. Losers: Galera Therapeutics (NASDAQ:GRTX) -68%, Atea Pharmaceutic...
Piper Sandler Technical Market Strategist Craig. W. Johnson is out with his latest quarterly Alpha Alignment Report, which screens 900 stocks for a host of fundamental and technical factors. Along with the headline Alpha Alignment Index, the report also screens for an equal-weighted Short Squ...
ODD for posoleucel adds to RMAT designation by FDA and OMP and PRIME designations by EMA Phase 3 registrational study of posoleucel in virus-associated hemorrhagic cystitis is ongoing AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today ann...
My readers will get the background on the stem cell transplant issues. I will offer a discussion on the uniqueness that AlloVir offers patients. The outstanding caliber and experience the management team brings to the creation of the company will be shared. For further detai...
Early clinical data show expansion and persistence of cells and support the efficacy and safety profile of ALVR109 in transplant and non-transplant patients with COVID-19 AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced preclinical an...
News, Short Squeeze, Breakout and More Instantly...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...